Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE
Breakthrough therapyHKG: 1801

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
BMSBristol-Myers Squibb

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

AstraZeneca's Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
AstraZenecaNASDAQ: AZN

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
Akeso BiopharmaCancer

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Show More